Ventrus crumbles following Diltiazem Phase III results

Ventrus Biosciences' (VTUS) shares collapse 61% after its Diltiazem Cream for patients with anal fissures failed to lower pain more than a placebo in a Phase III trial.

Diltiazem is designed to reduce pain associated with or following defecation by dilating the blood vessels that supply the associated region. (Previous)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs